{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T11:42:14Z","timestamp":1763811734635,"version":"3.41.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001823","name":"Ministerstvo \u0160kolstv\u00ed, Ml\u00e1de\u017ee a T\u011blov\u00fdchovy","doi-asserted-by":"publisher","award":["NU-21-03-00372"],"award-info":[{"award-number":["NU-21-03-00372"]}],"id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-06699-6","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T19:44:01Z","timestamp":1749843841000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Myomedin variants developed for in vitro PD-L1 diagnostics in tissue samples of non-small cell lung carcinoma patients"],"prefix":"10.1186","volume":"23","author":[{"given":"Hana","family":"Petrokov\u00e1","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna Maria","family":"Mierzwicka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prosenjit","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leona","family":"Ra\u0161kov\u00e1 Kafkov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jana","family":"Vaculov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jozef","family":"\u0160karda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ond\u0159ej","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petr","family":"Kosztyu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milan","family":"Kucha\u0159","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milan","family":"Ra\u0161ka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8118-0581","authenticated-orcid":false,"given":"Petr","family":"Mal\u00fd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,13]]},"reference":[{"key":"6699_CR1","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"ME Keir","year":"2008","unstructured":"Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677\u2013704.","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"6699_CR2","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13045-019-0779-5","volume":"12","author":"A Akinleye","year":"2019","unstructured":"Akinleye A, Rasool Z. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol. 2019;12(1):92.","journal-title":"J Hematol Oncol"},{"key":"6699_CR3","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.2147\/OTT.S105862","volume":"9","author":"X Wang","year":"2016","unstructured":"Wang X, Teng F, Kong L, Yu J. PD-L1 expression in human cancers and its association with clinical outcomes. OncoTargets Therapy. 2016;9:5023\u201339.","journal-title":"OncoTargets Therapy"},{"issue":"5","key":"6699_CR4","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S1471-4906(01)01888-9","volume":"22","author":"H Nishimura","year":"2001","unstructured":"Nishimura H, Honjo T. PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol. 2001;22(5):265\u20138.","journal-title":"Trends Immunol"},{"key":"6699_CR5","doi-asserted-by":"publisher","first-page":"961","DOI":"10.3389\/fimmu.2017.00961","volume":"8","author":"RM Gibbons Johnson","year":"2017","unstructured":"Gibbons Johnson RM, Dong H. Functional expression of programmed Death-Ligand 1 (B7-H1) by immune cells and tumor cells. Front Immunol. 2017;8:961.","journal-title":"Front Immunol"},{"issue":"8","key":"6699_CR6","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","volume":"8","author":"H Dong","year":"2002","unstructured":"Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793\u2013800.","journal-title":"Nat Med"},{"issue":"3","key":"6699_CR7","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41568-021-00431-4","volume":"22","author":"AVR Kornepati","year":"2022","unstructured":"Kornepati AVR, Vadlamudi RK, Curiel TJ. Programmed death ligand 1 signals in cancer cells. Nat Rev Cancer. 2022;22(3):174\u201389.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"6699_CR8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/BS9.0000000000000149","volume":"5","author":"YJ Zhou","year":"2023","unstructured":"Zhou YJ, Li G, Wang J, Liu M, Wang Z, Song Y, Zhang X, Wang X. PD-L1: expression regulation. Blood Sci. 2023;5(2):77\u201391.","journal-title":"Blood Sci"},{"key":"6699_CR9","doi-asserted-by":"publisher","first-page":"1342086","DOI":"10.3389\/fimmu.2024.1342086","volume":"15","author":"L Raskova Kafkova","year":"2024","unstructured":"Raskova Kafkova L, Mierzwicka JM, Chakraborty P, Jakubec P, Fischer O, Skarda J, Maly P, Raska M. NSCLC: from tumorigenesis, immune checkpoint misuse to current and future targeted therapy. Front Immunol. 2024;15:1342086.","journal-title":"Front Immunol"},{"issue":"6","key":"6699_CR10","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","volume":"18","author":"DB Doroshow","year":"2021","unstructured":"Doroshow DB, Bhalla S, Beasley MB, Sholl LM, Kerr KM, Gnjatic S, Wistuba II, Rimm DL, Tsao MS, Hirsch FR. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Reviews Clin Oncol. 2021;18(6):345\u201362.","journal-title":"Nat Reviews Clin Oncol"},{"issue":"8","key":"6699_CR11","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1097\/PAI.0000000000000256","volume":"23","author":"T Phillips","year":"2015","unstructured":"Phillips T, Simmons P, Inzunza HD, Cogswell J, Novotny J Jr., Taylor C, Zhang X. Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer. Appl Immunohistochem Mol Morphology: AIMM. 2015;23(8):541\u20139.","journal-title":"Appl Immunohistochem Mol Morphology: AIMM"},{"key":"6699_CR12","doi-asserted-by":"crossref","unstructured":"Kojima K, Sakamoto T, Kasai T, Kagawa T, Yoon H, Atagi S. PD-L1 expression as a predictor of postoperative recurrence and the association between the PD-L1 expression and mutations in NSCLC. Sci Rep-Uk; 2021. 11(1).","DOI":"10.1038\/s41598-021-96938-9"},{"issue":"6","key":"6699_CR13","doi-asserted-by":"publisher","first-page":"e0130142","DOI":"10.1371\/journal.pone.0130142","volume":"10","author":"L Carbognin","year":"2015","unstructured":"Carbognin L, Pilotto S, Milella M, Vaccaro V, Brunelli M, Calio A, Cuppone F, Sperduti I, Giannarelli D, Chilosi M, et al. Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed Death-Ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers. PLoS ONE. 2015;10(6):e0130142.","journal-title":"PLoS ONE"},{"issue":"1","key":"6699_CR14","first-page":"15","volume":"23","author":"S Vranic","year":"2023","unstructured":"Vranic S, Gatalica Z. PD-L1 testing by immunohistochemistry in immuno-oncology. Biomolecules Biomed. 2023;23(1):15\u201325.","journal-title":"Biomolecules Biomed"},{"issue":"1","key":"6699_CR15","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41379-019-0327-4","volume":"33","author":"E Torlakovic","year":"2020","unstructured":"Torlakovic E, Lim HJ, Adam J, Barnes P, Bigras G, Chan AWH, Cheung CC, Chung JH, Couture C, Fiset PO, et al. Interchangeability of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy. Mod Pathology: Official J United States Can Acad Pathol Inc. 2020;33(1):4\u201317.","journal-title":"Mod Pathology: Official J United States Can Acad Pathol Inc"},{"key":"6699_CR16","doi-asserted-by":"crossref","unstructured":"Maule JG, Clinton LK, Graf RP, Xiao J, Oxnard GR, Ross JS, Huang RSP. Comparison of PD-L1 tumor cell expression with 22C3, 28\u2013\u20098, and SP142 IHC assays across multiple tumor types. J Immunother Cancer. 2022; 10(10).","DOI":"10.1136\/jitc-2022-005573"},{"issue":"2","key":"6699_CR17","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/cts.12455","volume":"10","author":"H Scheerens","year":"2017","unstructured":"Scheerens H, Malong A, Bassett K, Boyd Z, Gupta V, Harris J, Mesick C, Simnett S, Stevens H, Gilbert H, et al. Current status of companion and complementary diagnostics: strategic considerations for development and launch. Clin Transl Sci. 2017;10(2):84\u201392.","journal-title":"Clin Transl Sci"},{"issue":"1","key":"6699_CR18","doi-asserted-by":"publisher","first-page":"62","DOI":"10.5858\/arpa.2021-0151-CP","volume":"147","author":"JE Willis","year":"2023","unstructured":"Willis JE, Eyerer F, Walk EE, Vasalos P, Bradshaw G, Yohe SL, Laser JS. Companion diagnostics: lessons learned and the path forward from the programmed death Ligand-1 rollout. Arch Pathol Lab Med. 2023;147(1):62\u201370.","journal-title":"Arch Pathol Lab Med"},{"issue":"34","key":"6699_CR19","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1200\/JCO.2017.74.7642","volume":"35","author":"R Buttner","year":"2017","unstructured":"Buttner R, Gosney JR, Skov BG, Adam J, Motoi N, Bloom KJ, Dietel M, Longshore JW, Lopez-Rios F, Penault-Llorca F, et al. Programmed Death-Ligand 1 immunohistochemistry testing: A review of analytical assays and clinical implementation in Non-Small-Cell lung Cancer. J Clin Oncology: Official J Am Soc Clin Oncol. 2017;35(34):3867\u201376.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"12","key":"6699_CR20","doi-asserted-by":"publisher","first-page":"6891","DOI":"10.21873\/anticanres.13065","volume":"38","author":"D Fujimoto","year":"2018","unstructured":"Fujimoto D, Yamashita D, Fukuoka J, Kitamura Y, Hosoya K, Kawachi H, Sato Y, Nagata K, Nakagawa A, Tachikawa R, et al. Comparison of PD-L1 assays in Non-small cell lung cancer: 22C3 pharmdx and SP263. Anticancer Res. 2018;38(12):6891\u20135.","journal-title":"Anticancer Res"},{"issue":"1","key":"6699_CR21","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1080\/21505594.2021.1920251","volume":"12","author":"M Kuchar","year":"2021","unstructured":"Kuchar M, Kosztyu P, Liskov\u00e1 VD, Cerny J, Petrokov\u00e1 H, Vr\u00f3blov\u00e1 E, Maly M, Vankov\u00e1 L, Krupka M, Kafkov\u00e1 LR, et al. Myomedin scaffold variants targeted to 10E8 HIV-1 broadly neutralizing antibody mimic gp41 epitope and elicit HIV-1 virus-neutralizing Sera in mice. Virulence. 2021;12(1):1271\u201387.","journal-title":"Virulence"},{"key":"6699_CR22","doi-asserted-by":"crossref","unstructured":"Liskov\u00e1 VD, Kosztyu P, Kuchar M, Cerny J, Bharadwaj S, Petrokov\u00e1 H, Vroblov\u00e1 E, Krupka M, Maly M, Zosincukov\u00e1 T et al. Myomedin replicas of gp120 V3 loop glycan epitopes recognized by PGT121 and PGT126 antibodies as non-cognate antigens for stimulation of HIV-1 broadly neutralizing antibodies. Front Immunol. 2022; 13.","DOI":"10.3389\/fimmu.2022.1066361"},{"key":"6699_CR23","doi-asserted-by":"crossref","unstructured":"Mierzwicka JM, Petrokov\u00e1 H, Kafkov\u00e1 LR, Kosztyu P, Cerny J, Kuchar M, Petr\u00edk M, Bendov\u00e1 K, Krasulov\u00e1 K, Groza Y et al. Engineering PD-1-targeted small protein variants for in vitro diagnostics and in vivo PET imaging. J Transl Med. 2024; 22(1).","DOI":"10.1186\/s12967-024-05210-x"},{"issue":"12","key":"6699_CR24","doi-asserted-by":"publisher","first-page":"118526","DOI":"10.1016\/j.bbamcr.2019.118526","volume":"1866","author":"S Azadi","year":"2019","unstructured":"Azadi S, Aboulkheyr Es H, Razavi Bazaz S, Thiery JP, Asadnia M, Ebrahimi Warkiani M. Upregulation of PD-L1 expression in breast cancer cells through the formation of 3D multicellular cancer aggregates under different chemical and mechanical conditions. Biochim Et Biophys Acta Mol Cell Res. 2019;1866(12):118526.","journal-title":"Biochim Et Biophys Acta Mol Cell Res"},{"issue":"5","key":"6699_CR25","first-page":"5399","volume":"18","author":"Y Zheng","year":"2019","unstructured":"Zheng Y, Fang YC, Li J. PD-L1 expression levels on tumor cells affect their immunosuppressive activity. Oncol Lett. 2019;18(5):5399\u2013407.","journal-title":"Oncol Lett"},{"issue":"7","key":"6699_CR26","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.jtho.2017.04.014","volume":"12","author":"X Gong","year":"2017","unstructured":"Gong X, Li X, Jiang T, Xie H, Zhu Z, Zhou F, Zhou C. Combined radiotherapy and Anti-PD-L1 antibody synergistically enhances antitumor effect in Non-Small cell lung Cancer. J Thorac Oncology: Official Publication Int Association Study Lung Cancer. 2017;12(7):1085\u201397.","journal-title":"J Thorac Oncology: Official Publication Int Association Study Lung Cancer"},{"issue":"6","key":"6699_CR27","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1007\/s10147-017-1161-7","volume":"22","author":"X Zhang","year":"2017","unstructured":"Zhang X, Zeng Y, Qu Q, Zhu J, Liu Z, Ning W, Zeng H, Zhang N, Du W, Chen C, et al. PD-L1 induced by IFN-gamma from tumor-associated macrophages via the JAK\/STAT3 and PI3K\/AKT signaling pathways promoted progression of lung cancer. Int J Clin Oncol. 2017;22(6):1026\u201333.","journal-title":"Int J Clin Oncol"},{"issue":"10","key":"6699_CR28","doi-asserted-by":"publisher","first-page":"10135","DOI":"10.1021\/acsnano.7b04717","volume":"11","author":"G Kwak","year":"2017","unstructured":"Kwak G, Kim D, Nam GH, Wang SY, Kim IS, Kim SH, Kwon IC, Yeo Y. Programmed cell death protein Ligand-1 Silencing with Polyethylenimine-Dermatan sulfate complex for dual Inhibition of melanoma growth. ACS Nano. 2017;11(10):10135\u201346.","journal-title":"ACS Nano"},{"key":"6699_CR29","doi-asserted-by":"publisher","first-page":"121518","DOI":"10.1016\/j.biomaterials.2022.121518","volume":"284","author":"P Zhang","year":"2022","unstructured":"Zhang P, Qin C, Liu N, Zhou X, Chu X, Lv F, Gu Y, Yin L, Liu J, Zhou J, et al. The programmed site-specific delivery of LY3200882 and PD-L1 SiRNA boosts immunotherapy for triple-negative breast cancer by remodeling tumor microenvironment. Biomaterials. 2022;284:121518.","journal-title":"Biomaterials"},{"issue":"1","key":"6699_CR30","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13000-018-0689-9","volume":"13","author":"M Udall","year":"2018","unstructured":"Udall M, Rizzo M, Kenny J, Doherty J, Dahm S, Robbins P, Faulkner E. PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics. Diagn Pathol. 2018;13(1):12.","journal-title":"Diagn Pathol"},{"key":"6699_CR31","doi-asserted-by":"publisher","first-page":"1401515","DOI":"10.3389\/fmed.2024.1401515","volume":"11","author":"M Badenhorst","year":"2024","unstructured":"Badenhorst M, Windhorst AD, Beaino W. Navigating the landscape of PD-1\/PD-L1 imaging tracers: from challenges to opportunities. Front Med. 2024;11:1401515.","journal-title":"Front Med"},{"issue":"1","key":"6699_CR32","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1001\/jamaoncol.2015.3638","volume":"2","author":"J McLaughlin","year":"2016","unstructured":"McLaughlin J, Han G, Schalper KA, Carvajal-Hausdorf D, Pelekanou V, Rehman J, Velcheti V, Herbst R, LoRusso P, Rimm DL. Quantitative assessment of the heterogeneity of PD-L1 expression in Non-Small-Cell lung Cancer. JAMA Oncol. 2016;2(1):46\u201354.","journal-title":"JAMA Oncol"},{"issue":"2","key":"6699_CR33","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1002\/cjp2.153","volume":"6","author":"A Dodson","year":"2020","unstructured":"Dodson A, Parry S, Lissenberg-Witte B, Haragan A, Allen D, O\u2019Grady A, McClean E, Hughes J, Miller K, Thunnissen E. External quality assessment demonstrates that PD-L1 22C3 and SP263 assays are systematically different. J Pathol Clin Res. 2020;6(2):138\u201345.","journal-title":"J Pathol Clin Res"},{"key":"6699_CR34","doi-asserted-by":"crossref","unstructured":"Xu HP, Lin G, Huang C, Zhu WF, Miao Q, Fan XR, Wu B, Zheng XB, Lin XD, Jiang K et al. Assessment of concordance between 22C3 and SP142 immunohistochemistry assays regarding PD-L1 expression in Non-Small cell lung Cancer. Sci Rep-Uk; 2017. 7.","DOI":"10.1038\/s41598-017-17034-5"},{"issue":"1","key":"6699_CR35","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/s10238-024-01404-1","volume":"24","author":"C Qi","year":"2024","unstructured":"Qi C, Li Y, Zeng H, Wei Q, Tan S, Zhang Y, Li W, Tian P. Current status and progress of PD-L1 detection: guiding immunotherapy for non-small cell lung cancer. Clin Exp Med. 2024;24(1):162.","journal-title":"Clin Exp Med"},{"key":"6699_CR36","doi-asserted-by":"publisher","first-page":"105520","DOI":"10.1016\/j.pep.2019.105520","volume":"166","author":"L Jing","year":"2020","unstructured":"Jing L, Liu J, Cui D, Li Y, Liu Z, Tao L, Zhao Q, Diao A. Screening and production of an affibody inhibiting the interaction of the PD-1\/PD-L1 immune checkpoint. Protein Exp Purif. 2020;166:105520.","journal-title":"Protein Exp Purif"},{"issue":"11","key":"6699_CR37","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.2967\/jnumed.117.191718","volume":"58","author":"DE Gonzalez Trotter","year":"2017","unstructured":"Gonzalez Trotter DE, Meng X, McQuade P, Rubins D, Klimas M, Zeng Z, Connolly BM, Miller PJ, O\u2019Malley SS, Lin SA, et al. In vivo imaging of the programmed death ligand 1 by (18)F PET. J Nuclear Medicine: Official Publication Soc Nuclear Med. 2017;58(11):1852\u20137.","journal-title":"J Nuclear Medicine: Official Publication Soc Nuclear Med"},{"issue":"3","key":"6699_CR38","first-page":"154","volume":"11","author":"NC Wong","year":"2021","unstructured":"Wong NC, Cai Y, Meszaros LK, Biersack HJ, Cook GJ, Ting HH, Mottaghy FM. Preclinical development and characterisation of (99m)Tc-NM-01 for SPECT\/CT imaging of human PD-L1. Am J Nucl Med Mol Imaging. 2021;11(3):154\u201366.","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"6","key":"6699_CR39","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1158\/1078-0432.CCR-18-1871","volume":"25","author":"A Natarajan","year":"2019","unstructured":"Natarajan A, Patel CB, Ramakrishnan S, Panesar PS, Long SR, Gambhir SS. A novel engineered small protein for positron emission tomography imaging of human programmed death Ligand-1: validation in mouse models and human Cancer tissues. Clin cancer Research: Official J Am Association Cancer Res. 2019;25(6):1774\u201385.","journal-title":"Clin cancer Research: Official J Am Association Cancer Res"},{"issue":"5","key":"6699_CR40","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1093\/protein\/gzz030","volume":"32","author":"S Ramakrishnan","year":"2019","unstructured":"Ramakrishnan S, Natarajan A, Chan CT, Panesar PS, Gambhir SS. Engineering of a novel subnanomolar affinity fibronectin III domain binder targeting human programmed death-ligand 1. Protein Eng Des Sel. 2019;32(5):231\u201340.","journal-title":"Protein Eng Des Sel"},{"issue":"47","key":"6699_CR41","doi-asserted-by":"publisher","first-page":"E6506","DOI":"10.1073\/pnas.1519623112","volume":"112","author":"RL Maute","year":"2015","unstructured":"Maute RL, Gordon SR, Mayer AT, McCracken MN, Natarajan A, Ring NG, Kimura R, Tsai JM, Manglik A, Kruse AC, et al. Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging. Proc Natl Acad Sci USA. 2015;112(47):E6506\u20136514.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"6699_CR42","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1021\/acschembio.0c00264","volume":"15","author":"G Kamalinia","year":"2020","unstructured":"Kamalinia G, Engel BJ, Srinivasamani A, Grindel BJ, Ong JN, Curran MA, Takahashi TT, Millward SW, Roberts RW. mRNA display discovery of a novel programmed death ligand 1 (PD-L1) binding peptide (a peptide ligand for PD-L1). ACS Chem Biol. 2020;15(6):1630\u201341.","journal-title":"ACS Chem Biol"},{"issue":"3","key":"6699_CR43","doi-asserted-by":"publisher","first-page":"529","DOI":"10.2967\/jnumed.117.199596","volume":"59","author":"DJ Donnelly","year":"2018","unstructured":"Donnelly DJ, Smith RA, Morin P, Lipovsek D, Gokemeijer J, Cohen D, Lafont V, Tran T, Cole EL, Wright M, et al. Synthesis and biologic evaluation of a novel (18)F-Labeled adnectin as a PET radioligand for imaging PD-L1 expression. J Nuclear Medicine: Official Publication Soc Nuclear Med. 2018;59(3):529\u201335.","journal-title":"J Nuclear Medicine: Official Publication Soc Nuclear Med"},{"issue":"12","key":"6699_CR44","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.2967\/jnumed.119.241364","volume":"61","author":"TS Stutvoet","year":"2020","unstructured":"Stutvoet TS, van der Veen EL, Kol A, Antunes IF, de Vries EFJ, Hospers GAP, de Vries EGE, de Jong S, Lub-de Hooge MN. Molecular imaging of PD-L1 expression and dynamics with the Adnectin-Based PET tracer (18)F-BMS-986192. J Nuclear Medicine: Official Publication Soc Nuclear Med. 2020;61(12):1839\u201344.","journal-title":"J Nuclear Medicine: Official Publication Soc Nuclear Med"},{"issue":"1","key":"6699_CR45","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13550-022-00906-x","volume":"12","author":"H Zhou","year":"2022","unstructured":"Zhou H, Bao G, Wang Z, Zhang B, Li D, Chen L, Deng X, Yu B, Zhao J, Zhu X. PET imaging of an optimized anti-PD-L1 probe (68)Ga-NODAGA-BMS986192 in immunocompetent mice and non-human primates. EJNMMI Res. 2022;12(1):35.","journal-title":"EJNMMI Res"},{"issue":"9","key":"6699_CR46","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.2967\/jnumed.120.258384","volume":"62","author":"S Robu","year":"2021","unstructured":"Robu S, Richter A, Gosmann D, Seidl C, Leung D, Hayes W, Cohen D, Morin P, Donnelly DJ, Lipov\u0161ek D, et al. Synthesis and preclinical evaluation of a (68)Ga-Labeled adnectin, (68)Ga-BMS-986192, as a PET agent for imaging PD-L1 expression. J Nuclear Medicine: Official Publication Soc Nuclear Med. 2021;62(9):1228\u201334.","journal-title":"J Nuclear Medicine: Official Publication Soc Nuclear Med"},{"key":"6699_CR47","doi-asserted-by":"publisher","first-page":"101202","DOI":"10.1016\/j.drup.2025.101202","volume":"79","author":"Y Wang","year":"2025","unstructured":"Wang Y, Liu Z, Li Y, Wang K, Yuan C, Shi J, Ren J, Wang S, Wang J, Zhao M, et al. Peptide-based PET\/CT imaging visualizes PD-L1-driven radioresistance in glioblastoma. Drug Resist Updates: Reviews Commentaries Antimicrob Anticancer Chemother. 2025;79:101202.","journal-title":"Drug Resist Updates: Reviews Commentaries Antimicrob Anticancer Chemother"},{"issue":"2","key":"6699_CR48","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s00259-023-06447-2","volume":"51","author":"M Zhou","year":"2024","unstructured":"Zhou M, Xiang S, Zhao Y, Tang Y, Yang J, Yin X, Tian J, Hu S, Du Y. [(68)Ga]Ga-AUNP-12 PET imaging to assess the PD-L1 status in preclinical and first-in-human study. Eur J Nucl Med Mol Imaging. 2024;51(2):369\u201379.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"6699_CR49","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s10637-022-01309-4","volume":"41","author":"Y Shima","year":"2023","unstructured":"Shima Y, Sato Y, Morimoto T, Hara S, Hirabayashi R, Nagata K, Nakagawa A, Tachikawa R, Hamakawa H, Takahashi Y, et al. Predictive performance of PD-L1 tumor proportion score for nivolumab response evaluated using archived specimens in patients with non-small cell lung cancer experiencing a postoperative recurrence. Invest New Drugs. 2023;41(1):35\u201343.","journal-title":"Invest New Drugs"},{"issue":"4","key":"6699_CR50","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/s41379-019-0372-z","volume":"33","author":"NL Lawson","year":"2020","unstructured":"Lawson NL, Dix CI, Scorer PW, Stubbs CJ, Wong E, Hutchinson L, McCall EJ, Schimpl M, DeVries E, Walker J, et al. Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies. Mod Pathology: Official J United States Can Acad Pathol Inc. 2020;33(4):518\u201330.","journal-title":"Mod Pathology: Official J United States Can Acad Pathol Inc"},{"issue":"1","key":"6699_CR51","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s13238-017-0412-8","volume":"9","author":"SG Tan","year":"2018","unstructured":"Tan SG, Liu KF, Chai Y, Zhang CWH, Gao S, Gao G, Qi JX. Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab. Protein Cell. 2018;9(1):135\u20139.","journal-title":"Protein Cell"},{"key":"6699_CR52","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.3389\/fimmu.2020.01088","volume":"11","author":"Y Chen","year":"2020","unstructured":"Chen Y, Pei Y, Luo J, Huang Z, Yu J, Meng X. Looking for the optimal PD-1\/PD-L1 inhibitor in Cancer treatment: A comparison in basic structure, function, and clinical practice. Front Immunol. 2020;11:1088.","journal-title":"Front Immunol"},{"issue":"1","key":"6699_CR53","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1021\/acs.jproteome.0c00521","volume":"20","author":"J Benicky","year":"2021","unstructured":"Benicky J, Sanda M, Brnakova Kennedy Z, Grant OC, Woods RJ, Zwart A, Goldman R. PD-L1 glycosylation and its impact on binding to clinical antibodies. J Proteome Res. 2021;20(1):485\u201397.","journal-title":"J Proteome Res"},{"key":"6699_CR54","doi-asserted-by":"publisher","first-page":"972046","DOI":"10.3389\/fphar.2022.972046","volume":"13","author":"A Zanello","year":"2022","unstructured":"Zanello A, Bortolotti M, Maiello S, Bolognesi A, Polito L. Anti-PD-L1 immunoconjugates for cancer therapy: are available antibodies good carriers for toxic payload delivering? Front Pharmacol. 2022;13:972046.","journal-title":"Front Pharmacol"},{"issue":"4","key":"6699_CR55","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/annonc\/mdy014","volume":"29","author":"J Adam","year":"2018","unstructured":"Adam J, Le Stang N, Rouquette I, Cazes A, Badoual C, Pinot-Roussel H, Tixier L, Danel C, Damiola F, Damotte D, et al. Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer. Ann Oncol. 2018;29(4):953\u20138.","journal-title":"Ann Oncol"},{"issue":"2","key":"6699_CR56","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1097\/PAI.0000000000000531","volume":"26","author":"ER Parra","year":"2018","unstructured":"Parra ER, Villalobos P, Mino B, Rodriguez-Canales J. Comparison of different antibody clones for immunohistochemistry detection of programmed cell death ligand 1 (PD-L1) on Non-Small cell lung carcinoma. Appl Immunohistochem Mol Morphology: AIMM. 2018;26(2):83\u201393.","journal-title":"Appl Immunohistochem Mol Morphology: AIMM"},{"key":"6699_CR57","doi-asserted-by":"crossref","unstructured":"Rimm DL, Han G, Taube JM, Yi ES, Bridge JA, Flieder DB, Homer R, West WW, Wu H, Roden AC et al. A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer. JAMA Oncol. 2017; 3(8):1051\u20131058.","DOI":"10.1001\/jamaoncol.2017.0013"},{"issue":"4","key":"6699_CR58","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/modpathol.2017.188","volume":"31","author":"M Tretiakova","year":"2018","unstructured":"Tretiakova M, Fulton R, Kocherginsky M, Long T, Ussakli C, Antic T, Gown A. Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression. Mod Pathol. 2018;31(4):623\u201332.","journal-title":"Mod Pathol"},{"issue":"1","key":"6699_CR59","doi-asserted-by":"publisher","first-page":"6830","DOI":"10.1038\/s41467-024-51242-8","volume":"15","author":"Z Shu","year":"2024","unstructured":"Shu Z, Dwivedi B, Switchenko JM, Yu DS, Deng X. PD-L1 deglycosylation promotes its nuclear translocation and accelerates DNA double-strand-break repair in cancer. Nat Commun. 2024;15(1):6830.","journal-title":"Nat Commun"},{"issue":"1","key":"6699_CR60","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12929-020-00670-x","volume":"27","author":"YN Wang","year":"2020","unstructured":"Wang YN, Lee HH, Hsu JL, Yu D, Hung MC. The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis. J Biomed Sci. 2020;27(1):77.","journal-title":"J Biomed Sci"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06699-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-06699-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06699-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T21:01:47Z","timestamp":1749848507000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-06699-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,13]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6699"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-06699-6","relation":{},"ISSN":["1479-5876"],"issn-type":[{"type":"electronic","value":"1479-5876"}],"subject":[],"published":{"date-parts":[[2025,6,13]]},"assertion":[{"value":"4 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors have read the journal\u2019s policy on disclosure of potential conflicts of interest and declared no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"655"}}